Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: GlaxoSmithKline Biologicals
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
Evaluation of immunogenicity and safety of two formulations of human rotavirus (HRV) vaccine, in healthy infants starting at age 6-12 weeks
•To demonstrate the lot-to-lot consistency of the PCV-free liquid HRV vaccine in terms of immunogenicity as measured by serum anti-RV IgA antibody concentrations 1-2 months after Dose 2. •To demonstr...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
A phase II, double-blind, multicentre, randomized study to demonstrate the non-inferiority of GlaxoSmithKline Biologicals’ thiomersal-free adjuvanted influenza vaccine compared to GlaxoSmithKline Biologicals thiomersal-reduced adjuvanted influenza vaccine in adults aged 65 years and above
To demonstrate the immunological non-inferiority (in terms of HI antibody GMT) of the thiomersal-free AS25 adjuvanted influenza vaccine compared to the thiomersal-reduced AS25 adjuvanted influenza vac...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
Study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Philippines
To assess the immunogenicity of GSK Biologicals’ HRV liquid vaccine versus placebo, in terms of anti-rotavirus Immunoglobulin A (IgA) antibody seroconversion at Month 3 (i.e. Visit 4), when administer...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
Immunogenicity and safety of two formulations of GSK Biologicals? pneumococcal vaccine (2830929A and 2830930A) when administered in healthy infants. Estudio de inmunogenicidad y seguridad de dos formulaciones de la vacuna antineumocócica de GSK Biologicals (2830929A y 2830930A) administrada en lactantes sanos
? To demonstrate that 2830929A vaccine co-administered with DTPa-HBV-IPV/Hib as a three-dose primary vaccination course at approximately 2, 3, 4 months of age is non-inferior to Prevenar 13 or Synflor...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
A phase III, open, multi-centre, controlled study to evaluate the long-term antibody persistence at 2 years, 3 years and 4 years after a single dose of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup A, C, W-135, Y- tetanus toxoid conjugate (MenACWY-TT) vaccine versus one dose of Meningitec™ administered in healthy 12 through 23-month old children who were primed in study MenACWY-TT-039 (109670) and to evaluate the immunogenicity and safety of a booster dose of the same meningococcal conjugate vaccine as given in the primary study, 4 years after priming
Immunogenicity Persistence At 24, 36, and 48 months after primary vaccination of toddlers with MenACWY-TT or Meningitec •To evaluate the persistence of meningococcal antibodies in terms of the percen...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
A study to evaluate the safety of GlaxoSmithKline HPV-16/18 L1 VLP AS04 vaccine who received the placebo control in the GSK HPV-015 study
To assess the safety of the HPV-16/18 L1 VLP AS04 vaccine throughout the study period.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
The long-term antibody persistence of GSK Biologicals’ meningo-coccal vaccine GSK134612 in healthy adolescents/adults
To evaluate the long-term persistence of the immunogen-icity induced by MenACWY-TT vaccine as compared to Menactra at 11-25 years of age in terms of the percentage of subjects with N. meningitidis ser...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
A phase II randomized, double-blind (observer blind), adjuvant justification study of RTS,S/AS01B and RTS,S/AS02A, candidate malaria vaccines, administered according to a 0, 1, 2 months schedule in malaria-naive adults aged 18 to 45 years
Immunogenicity • To demonstrate the superiority of anti-CS antibody response at 1 month post Dose 3 induced by RTS,S vaccine antigen formulated with AS01B adjuvant compared to RTS,S vaccine antigen ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
Safety and immunogenicity of new formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib vaccine (GSK217744) in primary infant vaccination
To demonstrate that the immunogenicity of at least one DTPa-HBVIPV/ Hib formulation is non-inferior to the licensed formulation in terms of seroprotection rates to diphtheria, tetanus, hepatitis B a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
Phase II, double blind, randomized, comparative study of the immunogenicity and safety of GlaxoSmithKline Biologicals’ modified formulation varicella vaccine and Varilrix™ given as a 2 dose course in the second year of life
To demonstrate the non-inferiority of Varilrix HSA-free vaccine as compared to Varilrix vaccines in terms of geometric mean titers (GMTs) of varicella antibodies 43 - 57 days after the first dose vacc...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
3
4
5
6
7
8
9
10
11
12
Next